Display options
Cite
Clark AS, Vahdat LT. Chemotherapy-induced palmar-plantar erythrodysesthesia syndrome: etiology and emerging therapies. Support Cancer Ther. 2004;1(4):213-8doi: 10.3816/SCT.2004.n.013.
Clark, A. S., & Vahdat, L. T. (2004). Chemotherapy-induced palmar-plantar erythrodysesthesia syndrome: etiology and emerging therapies. Supportive cancer therapy, 1(4), 213-8. https://doi.org/10.3816/SCT.2004.n.013
Clark, Amy S, and Vahdat, Linda T. "Chemotherapy-induced palmar-plantar erythrodysesthesia syndrome: etiology and emerging therapies." Supportive cancer therapy vol. 1,4 (2004): 213-8. doi: https://doi.org/10.3816/SCT.2004.n.013
Clark AS, Vahdat LT. Chemotherapy-induced palmar-plantar erythrodysesthesia syndrome: etiology and emerging therapies. Support Cancer Ther. 2004 Jul 01;1(4):213-8. doi: 10.3816/SCT.2004.n.013. PMID: 18628145.
Copy Download .nbib Format: NLM
Share it on

Support Cancer Ther. 2004 Jul 01;1(4):213-8. doi: 10.3816/SCT.2004.n.013.

Chemotherapy-induced palmar-plantar erythrodysesthesia syndrome: etiology and emerging therapies.

Supportive cancer therapy

Amy S Clark, Linda T Vahdat

Affiliations

  1. Division of Hematology/Medical Oncology, Weill Medical College of Cornell University, New York.

PMID: 18628145 DOI: 10.3816/SCT.2004.n.013

Abstract

Palmar-plantar erythrodysesthesia, or hand-foot syndrome (HFS), is emerging as a common, dose-dependent toxicity of many newer chemotherapy drugs. Frequently, HFS is a dose-limiting toxicity requiring discontinuation of treatment, chemotherapy dose reductions, or delays. The spectrum of symptoms of HFS can be mild, with erythema of the distal extremities, or it can be severe enough to interfere with activities of daily living. Although the exact mechanism is unknown, there are several approaches to ameliorating the symptoms of this complication. These include antiinflammatory agents, vitamin products, and peripheral vasoconstricting agents.

Publication Types